Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2015

01-02-2015 | Research Article

Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer

Authors: Juan Li, Ping Li, Tengfei Chen, Ge Gao, Xiaonan Chen, Yuwen Du, Ren Zhang, Rui Yang, Wei Zhao, Shaozhi Dun, Feng Gao, Guojun Zhang

Published in: Tumor Biology | Issue 2/2015

Login to get access

Abstract

MicroRNAs are implicated in the regulation of various cellular processes, including proliferation, differentiation, cell death, and cell mobility, and can function either as oncogenes or tumor suppressors in tumor progression. The effects of the expression of miR-96 in non-small cell lung cancer (NSCLC) remain unclear. In our study, qRT-PCR (quantitative reverse transcription PCR) was performed to identify the miR-96 expression level in 68 paired NSCLC and adjacent normal lung tissues. Trans-well, cell counting kit-8, and apoptosis assays were used to evaluate the effects of miR-96 expression on cell invasion, proliferation, and apoptosis. Dual-luciferase reporter assay and Western blotting were used to verify whether FOXO3 was a potential major target gene of miR-96. Finally, the effect of FOXO3 on miR-96-induced cell survival was determined by transfection of the genes expressing FOXO3 lacking 3′UTR and miR-96. The expression level of miR-96 in NSCLC tissues was higher than that in adjacent normal lung tissues, and this increased expression was significantly associated with lymph node metastasis. In contrast to the cells in the blank and negative control groups, the number of cells migrating through the matrigel was significantly lower and the incidence of apoptosis was significantly higher in cells transfected with a miR-96 inhibitor. Western blotting and dual-luciferase reporter assays demonstrated that miR-96 can bind to the putative seed region in FOXO3 mRNA 3′UTR, and can significantly lower the expression of FOXO3. The introduction of FOXO3 cDNA without 3′UTR restored miR-96 induced cell apoptosis and invasion. MiR-96 is up-regulated in NSCLC tissues. Downregulation of miR-96 inhibits invasion and promotes apoptosis in NSCLC cells A549 and SPC-A-1 by targeting FOXO3. Therefore, our study improves our understanding of the mechanisms underlying NSCLC pathogenesis and may promote the development of novel targeted therapies.
Literature
1.
Jemal A, Center MM, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.CrossRefPubMed
2.
Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91–112.CrossRefPubMed
3.
Favaretto AG, Pasello G, Magro C. Second and third line treatment in advanced non-small cell lung cancer. Discov Med. 2009;8(43):204–9.PubMed
4.
Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–16.CrossRefPubMed
5.
6.
Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.CrossRefPubMedPubMedCentral
7.
8.
9.
Garzon R, Marcucci G. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 2012;24:655–9.CrossRefPubMed
10.
Hoshino I, Matsubara H. MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today. 2013;43:467–78.CrossRefPubMed
11.
Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012;16:747–59.CrossRefPubMed
12.
Jones CI, Zabolotskaya MV, Newbury SF, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107:1987–96.CrossRefPubMedPubMedCentral
13.
14.
15.
Lin H, Dai T, Chen X, et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 2011;5:e15797.CrossRef
16.
17.
Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24:7410–25.CrossRefPubMed
18.
19.
Hu MC, Lee DF, Ou-Yang F, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004;117:225–37.CrossRefPubMed
20.
21.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;857–66.
22.
Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed
23.
Bandrés E, Cubedo E, Zárate R, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;29:1–10.
24.
Pineau P, Volinia S, Battiston C, et al. MiR-221 over-expression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264–9.CrossRefPubMed
25.
26.
Schaefer A, Jung M, Stephan C, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166–76.PubMed
27.
Agirre X, Jiménez-Velasco A, Bandrés E, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6:1830–40.CrossRefPubMed
28.
Zhu W, Liu X, Hunag Y, et al. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011;11:393.CrossRefPubMedPubMedCentral
29.
30.
Myatt SS, Wang J, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2010;70:367–77.CrossRefPubMed
31.
Jalvy-Delvaille S, Maurel M, Chabas S, et al. Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res. 2012;40:1356–65.CrossRefPubMed
32.
Yang JY, Zong CS, Ding QQ, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MCM2-mediated degradation. Nat Cell Biol. 2008;10:370.CrossRef
33.
Paik JH, Kollipara R, DePinho RA, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128(2):309–23.CrossRefPubMedPubMedCentral
34.
Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7(11):847–59.CrossRefPubMed
35.
Alvarez B. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature. 2001;413:744–7.CrossRefPubMed
36.
Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004;306:2105–8.CrossRefPubMed
37.
Tran H. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science. 2002;296:530–4.CrossRefPubMed
38.
39.
Furukawa-Hibi Y. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal. 2005;7:752–60.CrossRefPubMed
40.
41.
Brunet A. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–68.CrossRefPubMed
42.
Sunters A. FOXO3 transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003;278:49795–805.CrossRefPubMed
43.
44.
Hu MC. IκB kinase promotes tumourigenesis through inhibition of Forkhead FOXO3. Cell. 2004;117:225–37.CrossRefPubMed
45.
Seoane J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004;117:211–23.CrossRefPubMed
46.
Habashy HO. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat. 2011;129:11–21.CrossRefPubMed
47.
48.
49.
Miyamoto K. FOXO3 is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell. 2007;1:101–12.CrossRefPubMed
50.
Fei M. Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest. 2009;27:52–9.CrossRefPubMed
51.
Yang XB, Zhao JJ, Pan K, et al. Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients. PLoS One. 2013;8(10):e78158.CrossRefPubMedPubMedCentral
52.
Shukla S, Shukla M, Gupta S, et al. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol. 2009;34:1613–20.PubMedPubMedCentral
Metadata
Title
Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer
Authors
Juan Li
Ping Li
Tengfei Chen
Ge Gao
Xiaonan Chen
Yuwen Du
Ren Zhang
Rui Yang
Wei Zhao
Shaozhi Dun
Feng Gao
Guojun Zhang
Publication date
01-02-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2698-y

Other articles of this Issue 2/2015

Tumor Biology 2/2015 Go to the issue

Research Article

The SNAI1 3′UTR functions as a sponge for multiple migration-/invasion-related microRNAs

Research Article

The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling

Review

Post-transcriptional regulation of long noncoding RNAs in cancer

Research Article

Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer

Research Article

Britannin, a sesquiterpene lactone, inhibits proliferation and induces apoptosis through the mitochondrial signaling pathway in human breast cancer cells

Research Article

Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits